CSIMarket Company Name, Ticker, Suppliers, else..
 
Sarepta Therapeutics Inc   (SRPT)
Other Ticker:  
 
 
Price: $80.4000 $-2.21 -2.675%
Day's High: $83.5 Week Perf: -4.02 %
Day's Low: $ 80.14 30 Day Perf: -25.31 %
Volume (M): 1,135 52 Wk High: $ 159.89
Volume (M$): $ 91,270 52 Wk Avg: $119.61
Open: $82.72 52 Wk Low: $55.25



 Market Capitalization (Millions $) 7,147
 Shares Outstanding (Millions) 89
 Employees 1,400
 Revenues (TTM) (Millions $) 1,105
 Net Income (TTM) (Millions $) -691
 Cash Flow (TTM) (Millions $) -497
 Capital Exp. (TTM) (Millions $) 76

Sarepta Therapeutics Inc
Sarepta Therapeutics Inc is a biotechnology company that specializes in developing therapies for rare genetic diseases. The company is based in Cambridge, Massachusetts, and was founded in 1980.

Sarepta Therapeutics Inc focuses on developing and commercializing drugs for the treatment of Duchenne muscular dystrophy (DMD), a rare genetic disease that affects about 1 in every 3,500 males worldwide. The company's lead product candidate is a drug called eteplirsen, which is designed to treat DMD by repairing the genetic defects that cause the disease.

The company has a strong pipeline of other promising therapies, including drugs for the treatment of other types of muscular dystrophy and rare diseases such as limb-girdle muscular dystrophy, myotonic dystrophy, and spinal muscular atrophy.

Sarepta Therapeutics Inc has a robust research and development team made up of scientists, clinicians, and other experts with extensive experience in the field of genetic disease. The company has also built strong partnerships with academic institutions and other biotechnology companies, enabling it to access cutting-edge research and technology.

In addition to its drug development activities, Sarepta Therapeutics Inc is active in patient advocacy and education. The company works closely with patient advocacy groups and medical professionals to raise awareness about rare genetic diseases and to provide support to affected families. The company also sponsors research and educational programs, and provides financial assistance to families in need.

Sarepta Therapeutics Inc has a strong financial position, with a market capitalization of over $12 billion as of 2021, and a track record of revenue growth. The company has a broad investor base, including institutional investors, private equity firms, and individual investors.

Overall, Sarepta Therapeutics Inc is a successful biotechnology company that has made significant progress in developing therapies for rare genetic diseases. With its strong pipeline, experienced team, and commitment to patient advocacy, the company is well positioned for future growth and success.


   Company Address: 215 First Street Cambridge 2142 MA
   Company Phone Number: 274-4000   Stock Exchange / Ticker: NASDAQ SRPT
   SRPT is expected to report next financial results on February 27, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Lipocine Inc

the Major Pharmaceutical Preparations company in the fiscal time-frame ending September 30 2023

In its most recent fiscal period Lipocine Inc increased a shortfall per share at $-1.27 per share, opposite of $-0.03 per share a year before reporting season, In the prior reporting season LPCN realized $-0.68 per share.

Bioxytran Inc

Bioxytran Inc Faces Investor Concerns as Operating Deficit Grows in Q3 2023

Following the recent announcement of operating deficit for the third quarter of 2023, Bioxytran Inc, a major player in the pharmaceutical preparations industry, has captured investors' attention. The company's financial performance has raised questions about its ability to generate revenue in the near future.
For the third quarter of 2023, Bioxytran Inc reported an operating deficit of $-0.985464 million. This represents a worsening of the deficit compared to the same period in 2022, where it stood at $0.014225 million. However, the main concern for investors lies in the absence of any reported revenue during this time frame.
Briacell Therapeutics Corp

Briacell Therapeutics Corp Releases Fourth Quarter Fiscal Results - Showcasing Impressive Growth in Major Pharmaceutical Preparations Sector

The May to July 31, 2023 reporting season has resumed, and many companies, including those in the Major Pharmaceutical Preparations sector, have announced their financial numbers. Among these companies is Briacell Therapeutics Corp, which recently published an operating loss of $-7.705761 million for the financial fourth quarter of 2023. Additionally, Briacell Therapeutics Corp has reported a net deficit of $-14.300 million for the interval between May and July 31, 2023, which is a significant decline compared to the balanced books it maintained during the same period last year.
One noteworthy aspect is that the value of accounts receivable for Briacell Therapeutics Corp is still below the previous year's level; however, there has been some sequential progress. It is also important to mention that the company has observed a shortfall of $-20.30 million and has generated zero revenue during the financial period of 2023.
Gt Biopharma Inc

GTBP Reports Impressive Operating Surplus of $3.122 Million in Third Quarter Earnings Season

The stock market has always been a dynamic and exciting place, filled with ups and downs that keep investors on their toes. Today, we turn our attention to the Major Pharmaceutical Preparations industry and delve into the third quarter of 2023 numbers. Specifically, we examine Gt Biopharma Inc's financial report from July to September 30, 2023, which showcased an operating surplus of $3.122 million.
It's important to note that Gt Biopharma Inc has not cited any revenue yet, making the operating surplus even more impressive. As industry reporters analyze these figures, the prevailing situation of the organization becomes clearer. To truly understand the significance of the third quarter of 2023 earnings season, let's compare it with the same period in 2022.
Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc Overcomes Revenue Setback, Prepares for Resurgence in Q4 2023

Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.





 

Sarepta Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com